Cancer Therapy: Preclinical Targeting Src in Mucinous Ovarian Carcinoma
نویسندگان
چکیده
Purpose:Mucinous ovarian carcinomas have a distinct clinical pattern compared with other subtypes of ovarian carcinoma. Here, we evaluated (i) stage-specific clinical significance of mucinous ovarian carcinomas in a large cohort and (ii) the functional role of Src kinase in preclinical models of mucinous
منابع مشابه
Cancer Therapy: Preclinical Targeting Src and Tubulin in Mucinous Ovarian Carcinoma
Purpose: To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian
متن کاملTargeting SRC in mucinous ovarian carcinoma.
PURPOSE Mucinous ovarian carcinomas have a distinct clinical pattern compared with other subtypes of ovarian carcinoma. Here, we evaluated (i) stage-specific clinical significance of mucinous ovarian carcinomas in a large cohort and (ii) the functional role of Src kinase in preclinical models of mucinous ovarian carcinoma. EXPERIMENTAL DESIGN A total of 1,302 ovarian cancer patients including...
متن کاملTargeting SRC and tubulin in mucinous ovarian carcinoma.
PURPOSE To investigate the antitumor effects of targeting Src and tubulin in mucinous ovarian carcinoma. EXPERIMENTAL DESIGN The in vitro and in vivo effects and molecular mechanisms of KX-01, which inhibits Src pathway and tubulin polymerization, were examined in mucinous ovarian cancer models. RESULTS In vitro studies using RMUG-S and RMUG-L cell lines showed that KX-01 inhibited cell pro...
متن کاملAntiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Src, a nonreceptor tyrosine kinase, is a key mediator for multiple signaling pathways that regulate critical cellular functions and is often aberrantly activated in a number of solid tumors, including ovarian carcinoma. The purpose of this study was to determine the role of activated Src inhibition on tumor growth in an orthotopic murine model of ovarian carcinoma. In vitro studies on HeyA8 and...
متن کاملCancer Therapy: Preclinical Src Inhibition with Saracatinib Reverses Fulvestrant Resistance in ER-Positive Ovarian Cancer Models In Vitro and In Vivo
Purpose: More effective, less toxic treatments for recurrent ovarian cancer are needed. Although more than 60% of ovarian cancers express the estrogen receptor (ER), ER-targeted drugs have been disappointing due to drug resistance. In other estrogen-sensitive cancers, estrogen activates Src to phosphorylate p27 promoting its degradation and increasing cell-cycle progression. Because Src is acti...
متن کامل